<DOC>
	<DOCNO>NCT02310269</DOCNO>
	<brief_summary>This non-interventional , multinational , multi-center post-marketing study , document safety efficacy pasireotide s.c. administer routine clinical practice patient Cushing 's disease . Patients Cushing 's disease treat pasireotide s.c. alone combination therapy monitor . For study , enrol patient follow 3 year enrollment . Patients permanently discontinue pasireotide s.c. prior complete 3-year observation period follow 3 month last dose pasireotide s.c .</brief_summary>
	<brief_title>Long Term Safety Efficacy Pasireotide s.c. Patients With Cushing 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<criteria>Male female patient age 18 year old diagnosis Cushing 's disease surgery fail surgery option Patients must treat pasireotide s.c. start either first visit study prior study entry Patients ectopic ACTHdependent Cushing 's syndrome Patients adrenal Cushing 's syndrome Patients Pseudo Cushing 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cushing 's disease ,</keyword>
	<keyword>pasireotide s.c .</keyword>
	<keyword>Signifor</keyword>
</DOC>